Search - tctmd.com

Displaying 261 - 280 of 2016

Sort: Relevancy | Date

Presentation TCT 2020

Featured Clinical Research: (TCT36010) MOTIV BTK Pilot Study – Initial Safety and Performance Study of the MOTIV Sirolimus-Eluting Bioresorbable Coronary Scaffold; Initial Report on First 10 Patients

Presenter: Michel Bosiers

October 15, 2020

Presentation TCT 2020

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

Presenter: Roxana Mehran

October 15, 2020

News Conference News TCT 2020

DISRUPT CAD III: Lithotripsy Boosts Stent Expansion in Highly Calcified Lesions

L.A. McKeown

October 15, 2020

Presentation TCT 2020

Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease: The Disrupt CAD III Study

Presenter: Dean J. Kereiakes

October 15, 2020

Presentation TCT 2020

Catheter-Based Approach to Cardio Renal Unloading in HF (preCARDIA)

Presenter: Navin Kapur

October 15, 2020

Presentation TCT 2020

Closure of Iatrogenic Atrial Septal Defects Following Transcatheter Mitral Valve Repair – The Randomized MITHRAS Trial

Presenter: Philipp Lurz

October 15, 2020

News Conference News TCT 2020

MITHRAS: No Upside to Closing iASDs Caused by Transcatheter MV Interventions

Shelley Wood

October 15, 2020

Presentation TCT 2020

In My Opinion: How Should Revascularization Guidelines Change After ISCHEMIA?

Presenter: Davide Capodanno

October 15, 2020

Presentation TCT 2020

Transcatheter Tricuspid Valve Replacement 2.0 (VDyne)

Presenter: Azeem Latib

October 15, 2020

Presentation TCT 2020

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Presenter: Jeffrey W. Moses

October 15, 2020

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

News Conference News TCT 2020

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

Todd Neale

October 15, 2020

Presentation TCT 2020

ISCHEMIA in Perspective: Updated Meta-Analysis on PCI in SIHD

Presenter: Sripal Bangalore

October 15, 2020

Presentation TCT 2020

Natural Vascular Scaffolding for PVD Interventions (Alucent)

Presenter: Myles Greenberg

October 15, 2020

Presentation TCT 2020

Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: the SCOPE II randomised clinical trial

Presenter: Corrado Tamburino

October 15, 2020

Presentation TCT 2020

Critical Analysis and Clinical Implications From ISCHEMIA

Presenter: David Maron

October 15, 2020

Presentation TCT 2020

Yes! With the Right Training, Everyone Can (and Should) Do CTO PCI!

Presenter: Simon Walsh

October 15, 2020

Presentation TCT 2020

A Universal Nomenclature for CTO Terminology and Standardization of CTO PCI Trials: Introduction to CTO-ARC

Presenter: Luiz Ybarra

October 15, 2020

Presentation TCT 2020

Debate 2: Should CTO PCI Be Performed at Most Centers and by Most Operators? - No! CTO PCI Should Only Be Done by the Experts!

Presenter: Gerald Werner

October 15, 2020

Presentation TCT 2020

Device-Based Approaches to Infarct Size Reduction

Presenter: Giovanni Luigi De Maria

October 15, 2020

Advertisement

Featured Clinical Research: (TCT36010) MOTIV BTK Pilot Study – Initial Safety and Performance Study of the MOTIV Sirolimus-Eluting Bioresorbable Coronary Scaffold; Initial Report on First 10 Patients

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

DISRUPT CAD III: Lithotripsy Boosts Stent Expansion in Highly Calcified Lesions

Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease: The Disrupt CAD III Study

Catheter-Based Approach to Cardio Renal Unloading in HF (preCARDIA)

Closure of Iatrogenic Atrial Septal Defects Following Transcatheter Mitral Valve Repair – The Randomized MITHRAS Trial

MITHRAS: No Upside to Closing iASDs Caused by Transcatheter MV Interventions

In My Opinion: How Should Revascularization Guidelines Change After ISCHEMIA?

Transcatheter Tricuspid Valve Replacement 2.0 (VDyne)

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

ISCHEMIA in Perspective: Updated Meta-Analysis on PCI in SIHD

Natural Vascular Scaffolding for PVD Interventions (Alucent)

Comparison of self-expanding bioprostheses for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: the SCOPE II randomised clinical trial

Critical Analysis and Clinical Implications From ISCHEMIA

Yes! With the Right Training, Everyone Can (and Should) Do CTO PCI!

A Universal Nomenclature for CTO Terminology and Standardization of CTO PCI Trials: Introduction to CTO-ARC

Debate 2: Should CTO PCI Be Performed at Most Centers and by Most Operators? - No! CTO PCI Should Only Be Done by the Experts!

Device-Based Approaches to Infarct Size Reduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content